Cytokinetics (CYTK)

$64.73 -0.43 (-0.66%)
Market Cap 7.73B
Revenue (ttm) 18.47M
Net Income (ttm) -589.53M
EPS (ttm) N/A
PE Ratio 0.00
Forward PE N/A
Profit Margin -3,191.82%
Debt to Equity Ratio -0.38
Volume 1,434,900
Avg Vol 1,879,282
Day's Range N/A - N/A
Shares Out 122.27M
Stochastic %K 53%
Beta 0.55
Analysts Strong Sell
Price Target $89.37

Company Profile

Cytokinetics, Incorporated, a late-stage biopharmaceutical company, focuses on discovering, developing, and commercializing muscle activators and inhibitors as potential treatments for debilitating diseases in the United States. The company develops small molecule drug candidates primarily engineered to impact muscle function and contractility. Its drug candidates include omecamtiv mecarbil, a novel cardiac myosin activator that is in Phase III clinical trial in patients with heart failure. It a...

Industry: Biotechnology
Sector: Healthcare
Phone: 650 624 3000
Address:
350 Oyster Point Boulevard, South San Francisco, United States
BillionerOfKing
BillionerOfKing Feb. 3 at 8:23 PM
$CYTK Current Stock Price: $64.93 Contracts to trade: $65.0 CYTK Feb 20 2026 Call Entry: $3.70 Exit: $6.64 ROI: 80% Hold ~23 days Shared as daily free alerts and for educational purposes only. https://dailypickai.com/freealerts
0 · Reply
IN0V8
IN0V8 Feb. 3 at 5:51 PM
$CYTK Buying Opportunity Truist Securities raises target price to $92 from $84
0 · Reply
erevnon
erevnon Feb. 3 at 1:45 PM
Truist Securities maintains Cytokinetics $CYTK at Buy and raises the price target from $84 to https://marketsblock.com/stock-upgrades-and-downgrades/
0 · Reply
Night_Owl_Biotech
Night_Owl_Biotech Feb. 3 at 12:55 AM
The attached table notes the day of the week all 82 commercial-stage oncology (26) & non-oncology (56) bio M&A transactions were announced (those bios with 1st FDA approvals since 1/1/2013 so you won't see SGEN nor CELG for example). Roughly half of these M&A exits are announced on Mondays. In oncology its 62% of the time. Wednesday is the next most popular day of the week to announce acquisitions in this peer group. We track the dates M&A transactions are announced manually & use the "WEEKDAY" tool in excel to extrapolate the day of the week. In the past, we misread the "WEEKDAY" result by assuming 2 represented Tuesdays. Hence until we re-ran this analysis we thought Tuesdays were the most popular day to announce M&A trxs. We're going to run the same for clinical-stage bio M&A exits in the next few days. Our educated guesses of strong M&A candidates include: $SNDX $ARWR $CYTK $VKTX $XERS This is not investment advice. We're only sharing our analysis for entertainment purposes only.
0 · Reply
timfris
timfris Jan. 29 at 10:46 PM
$VKTX I’ve waited our $CYTK, $BBIO, and even $AUPH, this will be worth it too.
0 · Reply
SuperGreenToday
SuperGreenToday Jan. 29 at 9:02 PM
$CYTK Share Price: $65.59 Contract Selected: May 15, 2026 $65 Calls Buy Zone: $12.58 – $15.54 Target Zone: $21.23 – $25.95 Potential Upside: 59% ROI Time to Expiration: 105 Days | Updates via https://fxcapta.com/stockinfo/
0 · Reply
UsandThem7
UsandThem7 Jan. 29 at 6:42 PM
$CYTK it’s coming
0 · Reply
buyandsold
buyandsold Jan. 28 at 6:18 PM
$TRDA $CYTK green today deserves a rocket ship emoji
0 · Reply
Quantumup
Quantumup Jan. 28 at 1:22 PM
Barclays assumed coverage on $CYTK at an Overweight rating and an $87 PT. $BMY $EWTX Barclays said in its note: The Myqorzo launch kicked off today. Given a differentiated label with flexibility of titration, less Echo monitoring, and no DDI in Box Warning, we continue to view Myqorzo as a preferred drug over Camzyos in obstructive hypertrophic cardiomyopathy (oHCM). Our deep dive supported high probability of a positive outcome for Myqorzo in a Ph3 ACACIA trial (data expected in 2Q26) in non-obstructive hypertrophic cardiomyopathy (nHCM) with dual primary endpoints KCCQ-CSS (>75%) and pVO2 (>55%), supporting aficamten as the sole drug with both indications in HCM.
0 · Reply
Quantumup
Quantumup Jan. 27 at 7:55 PM
Truist reiterated $CYTK Buy-$84 and said, We remain buyers of CYTK following KOL feedback that recognizes Camzyos as a meaningful advance for HCM patients while indicating a tilt in clinical preference for MYQORZO, especially for new patient starts. $BMY $EWTX Truist added, While our earlier KOL checks were positive towards Camzyos (LINK1, LINK2, LINK3) as the sole approved CMI, we noted emerging signals that a differentiated label for aficamten could drive a preference. We think positive KOL sentiment supports our $3.7B WW peak sales est. (in-line w/ cons). Many KOLs believe beta-blockers will have a place in therapy, but that many will eventually progress to a CMIs. Virtual call w/ Dr. Masri on 2/3 at 10:00 am ET.
0 · Reply
Latest News on CYTK
Cytokinetics Announces MYQORZO™ (aficamten) Now Available in the U.S. for the Treatment of Adults with Symptomatic Obstructive Hypertrophic Cardiomyopathy to Improve Functional Capacity and Symptoms

Jan 27, 2026, 7:30 AM EST - 7 days ago

Cytokinetics Announces MYQORZO™ (aficamten) Now Available in the U.S. for the Treatment of Adults with Symptomatic Obstructive Hypertrophic Cardiomyopathy to Improve Functional Capacity and Symptoms

The Law Offices of Frank R. Cruz Announces Investigation of Cytokinetics, Incorporated (CYTK) on Behalf of Investors

Jan 22, 2026, 2:39 PM EST - 12 days ago

The Law Offices of Frank R. Cruz Announces Investigation of Cytokinetics, Incorporated (CYTK) on Behalf of Investors

Cytokinetics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Jan 20, 2026, 4:00 PM EST - 14 days ago

Cytokinetics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Cytokinetics, Incorporated (CYTK) Presents at 44th Annual J.P. Morgan Healthcare Conference Transcript

Jan 12, 2026, 3:46 PM EST - 22 days ago

Cytokinetics, Incorporated (CYTK) Presents at 44th Annual J.P. Morgan Healthcare Conference Transcript

Cytokinetics to Present at the 44th Annual J.P. Morgan Healthcare Conference

Jan 5, 2026, 4:00 PM EST - 4 weeks ago

Cytokinetics to Present at the 44th Annual J.P. Morgan Healthcare Conference

Cytokinetics: Small Label Differences With Big Commercial Stakes

Dec 22, 2025, 5:33 PM EST - 6 weeks ago

Cytokinetics: Small Label Differences With Big Commercial Stakes

Cytokinetics Wins FDA Nod For Heart Drug Myqorzo

Dec 22, 2025, 11:23 AM EST - 6 weeks ago

Cytokinetics Wins FDA Nod For Heart Drug Myqorzo

Cytokinetics, Incorporated (CYTK) Discusses FDA Approval of MYQORZO for Symptomatic Obstructive Hypertrophic Cardiomyopathy Transcript

Dec 22, 2025, 9:47 AM EST - 6 weeks ago

Cytokinetics, Incorporated (CYTK) Discusses FDA Approval of MYQORZO for Symptomatic Obstructive Hypertrophic Cardiomyopathy Transcript

US FDA approves Cytokinetics' heart disease drug

Dec 19, 2025, 4:08 PM EST - 6 weeks ago

US FDA approves Cytokinetics' heart disease drug

Cytokinetics Announces FDA Approval of MYQORZO™ (aficamten) for the Treatment of Adults with Symptomatic Obstructive Hypertrophic Cardiomyopathy to Improve Functional Capacity and Symptoms

Dec 19, 2025, 4:00 PM EST - 6 weeks ago

Cytokinetics Announces FDA Approval of MYQORZO™ (aficamten) for the Treatment of Adults with Symptomatic Obstructive Hypertrophic Cardiomyopathy to Improve Functional Capacity and Symptoms

Cytokinetics Announces NMPA Approval of MYQORZO® (aficamten) in China for Patients with Obstructive Hypertrophic Cardiomyopathy

Dec 17, 2025, 7:30 AM EST - 6 weeks ago

Cytokinetics Announces NMPA Approval of MYQORZO® (aficamten) in China for Patients with Obstructive Hypertrophic Cardiomyopathy

Cytokinetics Announces Inducement Grants Under Nasdaq Listing Rule 5635(C)(4)

Dec 16, 2025, 4:00 PM EST - 7 weeks ago

Cytokinetics Announces Inducement Grants Under Nasdaq Listing Rule 5635(C)(4)

Cytokinetics Announces Positive CHMP Opinion of MYQORZO® (Aficamten) for the Treatment of Obstructive Hypertrophic Cardiomyopathy

Dec 12, 2025, 8:42 AM EST - 7 weeks ago

Cytokinetics Announces Positive CHMP Opinion of MYQORZO® (Aficamten) for the Treatment of Obstructive Hypertrophic Cardiomyopathy

3 Potential Mid-Cap Biotech Buyout Targets In 2026

Dec 3, 2025, 6:22 PM EST - 2 months ago

3 Potential Mid-Cap Biotech Buyout Targets In 2026

COGT IBB TVTX XBI

Cytokinetics: A Heavily Mispriced Cardiovascular Platform

Nov 19, 2025, 7:40 AM EST - 2 months ago

Cytokinetics: A Heavily Mispriced Cardiovascular Platform

Cytokinetics Supports American Heart Association Initiative to Improve Care for People Living With Hypertrophic Cardiomyopathy

Nov 17, 2025, 8:10 AM EST - 2 months ago

Cytokinetics Supports American Heart Association Initiative to Improve Care for People Living With Hypertrophic Cardiomyopathy

INVESTOR DEADLINE APPROACHING: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Cytokinetics

Nov 12, 2025, 7:28 PM EST - 2 months ago

INVESTOR DEADLINE APPROACHING: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Cytokinetics

CYTK INVESTOR NOTICE: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Cytokinetics

Nov 10, 2025, 6:16 PM EST - 3 months ago

CYTK INVESTOR NOTICE: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Cytokinetics

Cytokinetics Presents Additional Data from MAPLE-HCM at the Hypertrophic Cardiomyopathy Medical Society Scientific Sessions and American Heart Association Scientific Sessions 2025

Nov 10, 2025, 7:30 AM EST - 3 months ago

Cytokinetics Presents Additional Data from MAPLE-HCM at the Hypertrophic Cardiomyopathy Medical Society Scientific Sessions and American Heart Association Scientific Sessions 2025

SHAREHOLDER NOTICE: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Cytokinetics

Nov 7, 2025, 10:01 AM EST - 3 months ago

SHAREHOLDER NOTICE: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Cytokinetics

Cytokinetics, Incorporated (CYTK) Q3 2025 Earnings Call Transcript

Nov 6, 2025, 4:46 AM EST - 3 months ago

Cytokinetics, Incorporated (CYTK) Q3 2025 Earnings Call Transcript

Cytokinetics Reports Third Quarter 2025 Financial Results and Provides Business Update

Nov 5, 2025, 4:00 PM EST - 3 months ago

Cytokinetics Reports Third Quarter 2025 Financial Results and Provides Business Update

Cytokinetics to Participate in November Investor Conferences

Nov 4, 2025, 4:00 PM EST - 3 months ago

Cytokinetics to Participate in November Investor Conferences

Cytokinetics Announces Upcoming Presentations at the Hypertrophic Cardiomyopathy Medical Society Scientific Sessions and American Heart Association Scientific Sessions 2025

Oct 31, 2025, 7:30 AM EDT - 3 months ago

Cytokinetics Announces Upcoming Presentations at the Hypertrophic Cardiomyopathy Medical Society Scientific Sessions and American Heart Association Scientific Sessions 2025

Cytokinetics has been on a tear as the biotech pioneers more drugs to fight heart ailments

Oct 28, 2025, 4:32 PM EDT - 3 months ago

Cytokinetics has been on a tear as the biotech pioneers more drugs to fight heart ailments

Cytokinetics CEO: Advancing a next gen opportunity which could expand addressable market

Oct 28, 2025, 3:08 PM EDT - 3 months ago

Cytokinetics CEO: Advancing a next gen opportunity which could expand addressable market

CYTK INVESTOR DEADLINE APPROACHING: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Cytokinetics

Oct 23, 2025, 1:37 PM EDT - 3 months ago

CYTK INVESTOR DEADLINE APPROACHING: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Cytokinetics

Cytokinetics to Announce Third Quarter Results on November 5, 2025

Oct 22, 2025, 4:00 PM EDT - 3 months ago

Cytokinetics to Announce Third Quarter Results on November 5, 2025

CYTK Investors Have Opportunity to Join Cytokinetics, Incorporated Fraud Investigation with the Schall Law Firm

Oct 7, 2025, 7:58 AM EDT - 4 months ago

CYTK Investors Have Opportunity to Join Cytokinetics, Incorporated Fraud Investigation with the Schall Law Firm

Shareholders who lost money in shares of Cytokinetics, Incorporated (NASDAQ: CYTK) Should Contact Wolf Haldenstein Immediately Lead Plaintiff Deadline is November 17, 2025

Sep 29, 2025, 4:21 PM EDT - 4 months ago

Shareholders who lost money in shares of Cytokinetics, Incorporated (NASDAQ: CYTK) Should Contact Wolf Haldenstein Immediately Lead Plaintiff Deadline is November 17, 2025

Cytokinetics Presents New Data Related to Aficamten at the HFSA Annual Scientific Meeting 2025

Sep 29, 2025, 7:30 AM EDT - 4 months ago

Cytokinetics Presents New Data Related to Aficamten at the HFSA Annual Scientific Meeting 2025

Shareholders who lost money in shares of Cytokinetics, Incorporated (NASDAQ: CYTK) Should Contact Wolf Haldenstein Immediately

Sep 25, 2025, 4:32 PM EDT - 4 months ago

Shareholders who lost money in shares of Cytokinetics, Incorporated (NASDAQ: CYTK) Should Contact Wolf Haldenstein Immediately

Cytokinetics Announces Call for Proposals for Its Eighth Annual Communications Grant Program

Sep 24, 2025, 7:30 AM EDT - 4 months ago

Cytokinetics Announces Call for Proposals for Its Eighth Annual Communications Grant Program

BillionerOfKing
BillionerOfKing Feb. 3 at 8:23 PM
$CYTK Current Stock Price: $64.93 Contracts to trade: $65.0 CYTK Feb 20 2026 Call Entry: $3.70 Exit: $6.64 ROI: 80% Hold ~23 days Shared as daily free alerts and for educational purposes only. https://dailypickai.com/freealerts
0 · Reply
IN0V8
IN0V8 Feb. 3 at 5:51 PM
$CYTK Buying Opportunity Truist Securities raises target price to $92 from $84
0 · Reply
erevnon
erevnon Feb. 3 at 1:45 PM
Truist Securities maintains Cytokinetics $CYTK at Buy and raises the price target from $84 to https://marketsblock.com/stock-upgrades-and-downgrades/
0 · Reply
Night_Owl_Biotech
Night_Owl_Biotech Feb. 3 at 12:55 AM
The attached table notes the day of the week all 82 commercial-stage oncology (26) & non-oncology (56) bio M&A transactions were announced (those bios with 1st FDA approvals since 1/1/2013 so you won't see SGEN nor CELG for example). Roughly half of these M&A exits are announced on Mondays. In oncology its 62% of the time. Wednesday is the next most popular day of the week to announce acquisitions in this peer group. We track the dates M&A transactions are announced manually & use the "WEEKDAY" tool in excel to extrapolate the day of the week. In the past, we misread the "WEEKDAY" result by assuming 2 represented Tuesdays. Hence until we re-ran this analysis we thought Tuesdays were the most popular day to announce M&A trxs. We're going to run the same for clinical-stage bio M&A exits in the next few days. Our educated guesses of strong M&A candidates include: $SNDX $ARWR $CYTK $VKTX $XERS This is not investment advice. We're only sharing our analysis for entertainment purposes only.
0 · Reply
timfris
timfris Jan. 29 at 10:46 PM
$VKTX I’ve waited our $CYTK, $BBIO, and even $AUPH, this will be worth it too.
0 · Reply
SuperGreenToday
SuperGreenToday Jan. 29 at 9:02 PM
$CYTK Share Price: $65.59 Contract Selected: May 15, 2026 $65 Calls Buy Zone: $12.58 – $15.54 Target Zone: $21.23 – $25.95 Potential Upside: 59% ROI Time to Expiration: 105 Days | Updates via https://fxcapta.com/stockinfo/
0 · Reply
UsandThem7
UsandThem7 Jan. 29 at 6:42 PM
$CYTK it’s coming
0 · Reply
buyandsold
buyandsold Jan. 28 at 6:18 PM
$TRDA $CYTK green today deserves a rocket ship emoji
0 · Reply
Quantumup
Quantumup Jan. 28 at 1:22 PM
Barclays assumed coverage on $CYTK at an Overweight rating and an $87 PT. $BMY $EWTX Barclays said in its note: The Myqorzo launch kicked off today. Given a differentiated label with flexibility of titration, less Echo monitoring, and no DDI in Box Warning, we continue to view Myqorzo as a preferred drug over Camzyos in obstructive hypertrophic cardiomyopathy (oHCM). Our deep dive supported high probability of a positive outcome for Myqorzo in a Ph3 ACACIA trial (data expected in 2Q26) in non-obstructive hypertrophic cardiomyopathy (nHCM) with dual primary endpoints KCCQ-CSS (>75%) and pVO2 (>55%), supporting aficamten as the sole drug with both indications in HCM.
0 · Reply
Quantumup
Quantumup Jan. 27 at 7:55 PM
Truist reiterated $CYTK Buy-$84 and said, We remain buyers of CYTK following KOL feedback that recognizes Camzyos as a meaningful advance for HCM patients while indicating a tilt in clinical preference for MYQORZO, especially for new patient starts. $BMY $EWTX Truist added, While our earlier KOL checks were positive towards Camzyos (LINK1, LINK2, LINK3) as the sole approved CMI, we noted emerging signals that a differentiated label for aficamten could drive a preference. We think positive KOL sentiment supports our $3.7B WW peak sales est. (in-line w/ cons). Many KOLs believe beta-blockers will have a place in therapy, but that many will eventually progress to a CMIs. Virtual call w/ Dr. Masri on 2/3 at 10:00 am ET.
0 · Reply
biochirp
biochirp Jan. 27 at 3:34 PM
$CYTK 85 wen
0 · Reply
MUHL
MUHL Jan. 27 at 3:13 PM
$CYTK time to go
0 · Reply
MillionTrader_xy
MillionTrader_xy Jan. 27 at 6:58 AM
$RVMD is $CYTK 2.0 next step Offering
0 · Reply
zmanx
zmanx Jan. 23 at 2:53 AM
$CYTK strong BO contender for 26!
0 · Reply
biochirp
biochirp Jan. 22 at 4:44 PM
$CYTK feel cheap with XBO running
0 · Reply
UsandThem7
UsandThem7 Jan. 22 at 3:51 PM
$CYTK let us go!
0 · Reply
erevnon
erevnon Jan. 20 at 3:23 PM
JP Morgan maintains Cytokinetics $CYTK at Overweight and raises the price target from $70 to https://marketsblock.com/stock-upgrades-and-downgrades/
0 · Reply
BillionerOfKing
BillionerOfKing Jan. 15 at 2:03 AM
$CYTK Current Stock Price: $64.60 Contracts to trade: $65 CYTK Jan 16 2026 Call Entry: $1.00 Exit: $1.26 ROI: 26% Hold ~20 days Shared as daily free alerts and for educational purposes only. https://dailypickai.com/freealerts
0 · Reply
timfris
timfris Jan. 13 at 7:34 PM
$CYTK would be nice if this got taken out. Fully loaded but still add on dips like today. $115 would be nice.
2 · Reply
OfficialStocktwitsUser
OfficialStocktwitsUser Jan. 13 at 1:30 PM
$CYTK RSI: 54.26, MACD: 0.1403 Vol: 1.48, MA20: 62.93, MA50: 63.63 🔴 SELL - Downtrend 👉 https://quantumstockalerts.com Disclaimer: I am not a financial advisor. This post reflects personal analysis and opinions only. Please do your own research before investing or trading.
0 · Reply
UsandThem7
UsandThem7 Jan. 12 at 8:40 PM
$CYTK silver of the stock market.
0 · Reply
OptionRunners
OptionRunners Jan. 12 at 6:17 PM
$CYTK they rolled the April's out to May and added back to the position. Currently presenting at JPM.
0 · Reply